

08:30 - 09:	25	Registration and Coffee			
09:25 - 09:	09:25 - 09:30 Welcome				
09:30 - 11:00		What's new in NETs? ENETS guidelines update (new recommendations applied to interactive cases), UK epidemiology and genetics Chairs: Andrea Frilling (London) & Martin Weickert (Coventry)			
		09:30 Midgut NETs – <i>Mohid Khan (Cardiff)</i>			
		09:50 Pancreatic NETs - Judith Cave (Southampton)	9:50 Pancreatic NETs - Judith Cave (Southampton)		
		10:10 Bronchial NETs - Wasat Mansoor (Manchester)	0:10 Bronchial NETs - Wasat Mansoor (Manchester)		
		10:30 Update on national incidence data from Public Health Engla	0:30 Update on national incidence data from Public Health England (PHE) - John Ramage (London)		
		10:45 Where NETs fit in with the 100,000 genome project – <i>Clare</i>	0:45 Where NETs fit in with the 100,000 genome project – Clare Craig (London)		
11:00 - 11:30		Coffee, Exhibition and Posters			
11:30 - 12:45		Management of Phaeochromocytoma/Paraganglioma Chairs: Maralyn Druce (London) & David Scott-Coombes (Cardiff)			
		11:30 Clinician viewpoint – Simon Aylwin (London)			
		11:55 Special considerations in the management of patients with f	11:55 Special considerations in the management of patients with familial Phaeochromocytoma/Paraganglioma syndromes - <i>Scott Akker (London)</i>		
		12:20 Imaging viewpoint - Shaunakk Navalkissoor (London)			
12:45 - 13:00		AGM	AGM		
13:00 - 14:00		Lunch, Exhibition & Posters			
14:00 - 14:45		Debate: This house believes management of patients with NETs should be undertaken by Chair: Christos Toumpanakis (London)			
		14:00 Oncologists Nick Reed (Glasgow)			
		14:05 Gastroenterologists Martyn Caplin (London)			
		14:10 Endocrinologists Ashley Grossman (Oxford)			
		14:15 Discussion with audience participation & case studies			
-		clinical session E Barbara King (London) & Nickie Jervis (London) 14:45 -		Slational Science Session Chrissie Thirlwell (London)	
	14:45	Survey of the Somatostatin Analogue use in the UK Mike Tadman (Oxford)	14:45	patients with advanced pancreatic neuroendocrine	
	15:00	Syndrome		tumours (pNETs) with exceptional responses vs. poor responders to targeted therapies Jorge Barriuso (Manchester)	
		Liz Friend (Basingstoke)	15:05	Immunotherapy in solid tumours, determination of immune-response and where this might lead in NETs	
				Christian Ottensmeier (Southampton)	
15:30 - 16:00		Coffee, Exhibition and Posters			
16:00 - 16:30		Oral Communications Chairs: John Ayuk (Birmingham) & Mark Pritchard (Liverpool)			
		16:00 Netazepide, a gastrin/CCK ₂ receptor antagonist, can eradicate atrophic gastritis – <i>Malcom Boyce (London)</i>	gastric neuroen	docrine tumours in patients with autoimmune chronic	
		Tumour Size is Not a Reliable Criterion for Management of Patients with Non-Secreting Pancreatic Neuroendocrine Tumours: Results of a Large, Multi-Centre, Operative Cohort – Logan Mills (Coventry)			
		20 Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome not Adequately Controlled by Somatostatin Analog Therapy: Analysis of the Ongoing TELESTAR Extension Period – Martin Caplin (Slough)			
16:30 - 17:00		Plenary Speaker & Trials update Chair: Tim Meyer (London)			
		16:30 New treatments and advances in NETs- Rajesh Thakker (Oxfor	rd)		
		17:00 Trials update – <i>Juan Valle (Manchester)</i>			
		11.00 Inab apaate – Juan valle (Manchester)			

17:20 - 17:30 Prize giving & closing

Wine & cheese

17:30